Ultrasensitive circulating tumor DNA analysis improves detection of molecular residual disease in locally advanced esophageal cancer.
More sensitive blood tests for cancer DNA remnants after surgery help doctors decide who truly needs additional chemotherapy.
This study applied MAESTRO-Pool ultrasensitive ctDNA technology to 331 plasma samples from 36 esophageal cancer patients, demonstrating markedly improved MRD detection compared to conventional ctDNA assays. Accurate postoperative MRD detection in esophageal cancer has direct implications for adjuvant therapy selection.
What the study was
- Study design
- Prospective analytical study
- Population
- 36 locally advanced esophageal cancer patients, 331 plasma samples
- Sample size
- 36
- Category
- Early Detection
- Maturity
- Exploratory
- Journal
- Clinical cancer research : an official journal of the American Association for Cancer Research
Why it surfaced
Demonstrates significant sensitivity improvement in ctDNA MRD detection; esophageal cancer has high unmet need; requires validation in larger cohorts.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.